How loss of the ARID1A gene and estrogen work together in endometrial cancer
The combined role of ARID1A loss and estrogen signaling in endometrial cancer
This project looks at how losing the ARID1A gene and estrogen signals together change endometrial cancer cells in people with estrogen-driven endometrial cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Utah State Higher Education System--University of Utah NIH-funded |
| Lab location | 1 site (Salt Lake City, United States) |
| Project ID | NIH-11296837 on NIH RePORTER |
What this research studies
From a patient perspective, the team will use lab-grown 3D cell cultures and animal models to mimic estrogen-driven endometrial tumors that lack the ARID1A gene. They will study how ARID1A loss alters estrogen receptor activity and the gene programs that drive tumor growth. The researchers will test whether other chromatin remodeling proteins or pathways become dependences when ARID1A is lost. Findings could point to biological weaknesses that might be targeted by new treatments for this cancer subtype.
Who could benefit from this research
Good fit: People with endometrioid (type I) endometrial cancer, especially tumors that are estrogen receptor–positive and carry ARID1A mutations, would be most directly relevant.
Not a fit: Patients with non-endometrioid (type II) or estrogen receptor–negative endometrial cancers, or tumors without ARID1A alterations, are less likely to benefit directly from these findings.
Why it matters
Potential benefit: If successful, this work could reveal new drug targets or treatment strategies for people with ARID1A-altered, estrogen-responsive endometrial cancer.
How similar studies have performed: Previous studies have linked ARID1A loss to endometrial cancer and suggested interactions with estrogen signaling, but turning those insights into effective therapies remains largely unproven.
Where this research is happening
Salt Lake City, United States
- Utah State Higher Education System--University of Utah — Salt Lake City, United States (Active)
Researchers
- Principal investigator: Gertz, Jason — Utah State Higher Education System--University of Utah
- Study coordinator: Gertz, Jason
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.